For regions where toripalimab is unavailable, other PD-1/PD-L1 inhibitors (nivolumab or pembrolizumab) may be substituted with axitinib, given their shared mechanisms of action and proven efficacy in RCC. The gene discussed is CD274; the disease is renal cell carcinoma.